keyword
MENU ▼
Read by QxMD icon Read
search

Immuno therapy

keyword
https://www.readbyqxmd.com/read/29660428/the-kinetics-of-anti-drug-antibodies-drug-levels-and-clinical-outcomes-in-infliximab-exposed-patients-with-immuno-mediated-disorders
#1
Nencini Francesca, Vultaggio Alessandra, Pratesi Sara, Cammelli Daniele, Milla Monica, Fiori Ginevra, Bagnoli Siro, Prignano Francesca, Romagnani Sergio, Maggi Enrico, Matucci Andrea
BACKGROUND: Hypersensitivity reactions (HRs) and loss of response (LOR) to infliximab (IFX) are related to drug immunogenicity characterized by anti-drug antibodies (ADA). OBJECTIVE: To analyse the timing of ADA appearance, and its relationship with drug levels and clinical outcomes in IFX-treated patients with different diseases. METHODS: Samples were longitudinally collected before each infusion from 91 IFX-treated patients and were assayed for ADA and drug levels by ELISA and for IgE by CAP-system Clinical data were also monitored, regarding efficacy and safety of therapy...
April 13, 2018: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/29656021/next-generation-neuro-oncology
#2
REVIEW
Michael Weller
Neuro-oncology has evolved as a growing, but still small, highly specialised and multidisciplinary field at the interface of several diagnostic and therapeutic disciplines. The major challenge in the field of primary tumours is to translate the almost unique progress in deciphering the highly complex molecular genetic nature of many primary brain tumours, notably glioblastoma, into advances that allow for clinical benefit for affected patients. Furthermore, metastases to the central nervous system are an increasingly prevalent complication in many systemic cancers...
April 12, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29653177/additive-potential-of-combination-therapy-against-cryptococcosis-employing-a-novel-amphotericin-b-and-fluconazole-loaded-dual-delivery-system
#3
Azmat Ali Khan, Amer M Alanazi, Mumtaz Jabeen, Shahnavaj Khan, Abdul Mallik
Cryptococcus neoformans is one of the most lethal fungi causing mortality across the globe with the highest incidences in immuno-compromised person. Patients taking immuno-suppressive medications and immuno-competent hosts are extremely susceptible to its infection. Thus, new forms of therapy are urgently required for effective cure to the fungal burden. So, in the present study we have tried to explore the potential effects of amphotericin B (AMB) and fluconazole (FLC) in combination antifungal drug therapy...
April 10, 2018: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/29652798/the-double-face-of-exosome-carried-micrornas-in-cancer-immunomodulation
#4
REVIEW
Romina Alfonsi, Ludovica Grassi, Michele Signore, Désirée Bonci
In recent years many articles have underlined the key role of nanovesicles, i.e., exosomes, as information carriers among biological systems including cancer. Tumor-derived exosomes (TEXs) are key players in the dynamic crosstalk between cancer cells and the microenvironment while promote immune system control evasion. In fact, tumors are undoubtedly capable of silencing the immune response through multiple mechanisms, including the release of exosomes. TEXs have been shown to boost tumor growth and promote progression and metastatic spreading via suppression or stimulation of the immune response towards cancer cells...
April 13, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29651946/neoadjuvant-therapy-is-essential-for-resectable-pancreatic-cancer
#5
Jin-Zhi Xu, Wen-Quan Wang, Shi-Rong Zhang, Hua-Xiang Xu, Chun-Tao Wu, Zi-Hao Qi, He-Li Gao, Shuo Li, Quan-Xing Ni, Xian-Jun Yu, Liang Liu
BACKGROUND: Awareness of the benefits of neoadjuvant therapy is increasing, but its use as an initial therapeutic option for patients with resectable pancreatic cancer remains controversial, especially for those patients without high-risk prognostic features. Even for patients with high-risk features who are candidates to receive neoadjuvant therapy, no standard regimen exists. METHODS: In this review, we examined available data on neoadjuvant therapy in patients with resectable pancreatic cancer, including prospective studies, retrospective studies, and ongoing clinical trials, by searching PubMed/MEDLINE, ClinicalTrials...
April 12, 2018: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/29651939/role-of-sertoli-cell-proteins-in-immunomodulation
#6
Giovanni Luca, Tiziano Baroni, Iva Arato, Barbara Hansen, Don Cameron, Riccardo Calafiore
Several publications have been written reviewing the basic physiology of the mammalian Sertoli cell, but the aim of this review is to summarize some of the recent findings regarding the immunomodulatory role of Sertoli cells, and especially the key Sertoli cell regulatory proteins that are associated with the well-defined immune privileged status of the testis. A better definition and understanding of these Sertoli cell proteins and the mechanisms of immuno-protection should help to elucidate their role in damage of the spermatogenic process and their role in cell therapy for a number of cell-mediated chronic diseases...
April 12, 2018: Protein and Peptide Letters
https://www.readbyqxmd.com/read/29643471/current-state-of-immunotherapy-for-glioblastoma
#7
REVIEW
Michael Lim, Yuanxuan Xia, Chetan Bettegowda, Michael Weller
Glioma is the most common primary cancer of the central nervous system, and around 50% of patients present with the most aggressive form of the disease, glioblastoma. Conventional therapies, including surgery, radiotherapy, and pharmacotherapy (typically chemotherapy with temozolomide), have not resulted in major improvements in the survival outcomes of patients with glioblastoma. Reasons for this lack of progress include invasive tumour growth in an essential organ, which limits the utility of local therapy, as well as the protection of tumour cells by the blood-brain barrier, their intrinsic resistance to the induction of cell death, and lack of dependence on single, targetable oncogenic pathways, all of which impose challenges for systemic therapy...
April 11, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/29629216/novel-systemic-therapies-for-advanced-gastric-cancer
#8
REVIEW
Hong Jun Kim, Sang Cheul Oh
Gastric cancer (GC) is the second leading cause of cancer mortality and the fourth most commonly diagnosed malignant diseases. While continued efforts have been focused on GC treatment, the introduction of trastuzumab marked the beginning of a new era of target-specific treatments. Considering the diversity of mutations in GC, satisfactory results obtained from various target-specific therapies were expected, yet most of them were unsuccessful in controlled clinical trials. There are several possible reasons underlying the failures, including the absence of patient selection depending on validated predictive biomarkers, the inappropriate combination of drugs, and tumor heterogeneity...
March 2018: Journal of Gastric Cancer
https://www.readbyqxmd.com/read/29605492/comparative-analysis-on-the-dynamic-of-lacrimal-gland-damage-and-regeneration-after-interleukin-1%C3%AE-or-duct-ligation-induced-dry-eye-disease-in-mice
#9
Jana Dietrich, Carlo Schlegel, Mathias Roth, Joana Witt, Gerd Geerling, Sonja Mertsch, Stefan Schrader
The loss of functional lacrimal gland (LG) tissue causes quantitative tear deficiency and is the most common reason for the development of severe dry eye disease (DED). The induction of LG regeneration in situ would be a promising approach to curatively treat DED, but underlying mechanisms are mainly unclear. Therefore, this study aims to comparatively evaluate the dynamic of LG damage and regeneration in two mouse models in order to study mechanisms of LG regeneration. Male C57BL/6 J mice were used to induce damage to the right extraorbital LG either by a single interleukin (IL) 1α injection or a ligation of the secretory duct for 7 days...
March 29, 2018: Experimental Eye Research
https://www.readbyqxmd.com/read/29600022/expanding-role-for-radiotherapy-in-metastatic-non-small-cell-lung-cancer-in-the-era-of-targeted-therapy-and-immuno-oncology
#10
EDITORIAL
Elaine Luterstein, Percy Lee
No abstract text is available yet for this article.
January 2018: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29596381/resveratrol-suppresses-the-growth-and-enhances-retinoic-acid-sensitivity-of-anaplastic-thyroid-cancer-cells
#11
Yi-Tian Li, Xiao-Ting Tian, Mo-Li Wu, Xu Zheng, Qing-You Kong, Xiao-Xin Cheng, Guang-Wen Zhu, Jia Liu, Hong Li
Anaplastic thyroid cancer (ATC) is a highly lethal undifferentiated malignancy without reliable therapies. Retinoic acid (RA) has been employed to promote redifferentiation of thyroid cancers by increasing their I131 uptake and radio-sensitivity, but its effect(s) on ATCs has not yet been ascertained. Likewise, resveratrol induces cancer redifferentiation but, also in this case, its effects on ATCs remain unknown. These issues have been addresses in the current study using three human ATC cell lines (THJ-11T, THJ-16T, and THJ-21T) through multiple experimental approaches...
March 29, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29596308/ep4-as-a-therapeutic-target-for-aggressive-human-breast-cancer
#12
REVIEW
Mousumi Majumder, Pinki Nandi, Ahmed Omar, Kingsley Chukwunonso Ugwuagbo, Peeyush K Lala
G-protein-coupled receptors (GPCRs, also called seven-transmembrane or heptahelical receptors) are a superfamily of cell surface receptor proteins that bind to many extracellular ligands and transmit signals to an intracellular guanine nucleotide-binding protein (G-protein). When a ligand binds, the receptor activates the attached G-protein by causing the exchange of Guanosine-5'-triphosphate (GTP) for guanosine diphosphate (GDP). They play a major role in many physiological functions, as well as in the pathology of many diseases, including cancer progression and metastasis...
March 29, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29593890/neoadjuvant-and-consolidation-immuno-oncology-therapy-in-stage-iii-non-small-cell-lung-cancer
#13
REVIEW
Justin Yeh, Kristen A Marrone, Patrick M Forde
Lung cancer continues to be the leading cause of cancer death worldwide. Recently, immunotherapy for non-small cell lung cancer (NSCLC) has emerged as a powerful treatment option for advanced lung cancer. The relative success of programmed death 1 (PD-1) and/or programmed death ligand 1 (PD-L1) antibodies in metastatic disease have increased interest in expanding their use to earlier stage NSCLC. The complex and diverse nature of stage III disease also invites the incorporation of immunotherapy into treatment plans in both the neoadjuvant and consolidation settings...
February 2018: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29587322/-the-role-of-biomarkers-in-the-diagnosis-prognosis-and-therapy-of-patients-with-immuno-oncological-treatments-of-genito-urinary-carcinomas
#14
Eva Compérat, Caroline Eymerit, Julien Moroch, Justin Varinot
In recent years, fundamental research has yielded new insights into tumour biology, and new treatments have been developed. This review highlights the role of the pathologist and how he can support clinicians to find the right treatment for each patient. We explain the problems of the molecular subgroups of bladder cancer, the role of neo-adjuvant chemotherapy in the context of these findings, and show the important role of checkpoint inhibitors. Furthermore we focus on kidney cancer, with the clear cell carcinoma as the most frequent tumour type...
April 2018: Aktuelle Urologie
https://www.readbyqxmd.com/read/29581255/anti-ctla-4-therapy-requires-an-fc-domain-for-efficacy
#15
Jessica R Ingram, Olga S Blomberg, Mohammad Rashidian, Lestat Ali, Scott Garforth, Elena Fedorov, Alexander A Fedorov, Jeffrey B Bonanno, Camille Le Gall, Stephanie Crowley, Camilo Espinosa, Tamara Biary, Edmund J Keliher, Ralph Weissleder, Steven C Almo, Stephanie K Dougan, Hidde L Ploegh, Michael Dougan
Ipilimumab, a monoclonal antibody that recognizes cytotoxic T lymphocyte antigen (CTLA)-4, was the first approved "checkpoint"-blocking anticancer therapy. In mouse tumor models, the response to antibodies against CTLA-4 depends entirely on expression of the Fcγ receptor (FcγR), which may facilitate antibody-dependent cellular phagocytosis, but the contribution of simple CTLA-4 blockade remains unknown. To understand the role of CTLA-4 blockade in the complete absence of Fc-dependent functions, we developed H11, a high-affinity alpaca heavy chain-only antibody fragment (VHH) against CTLA-4...
March 26, 2018: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/29580733/the-administration-of-adjuvant-chemo-immuno-therapy-in-the-post-acosog-z0011-era-a-population-based-study
#16
Ingrid G M Poodt, Marjolijn L Rots, Guusje Vugts, Thijs van Dalen, Anne Kuijer, Birgit E P J Vriens, Grard A P Nieuwenhuijzen, Robert-Jan Schipper
PURPOSE: The ACOSOG-Z0011-study has resulted in a trend to a more conservative treatment of the axilla for selected sentinel-node-positive patients. However, axillary nodal involvement has always been an important factor for tumor staging and tailoring adjuvant chemotherapy plans. This study evaluates the impact of omitting completion axillary lymph node dissection (cALND) on the administration of adjuvant chemo (-immuno)therapy in Dutch clinical T1-2N0M0 (cT1-2N0M0) sentinel-node-positive breast cancer patients...
March 14, 2018: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29574334/immuno-oncology-in-head-and-neck-squamous-cell-cancers-news-from-clinical-trials-emerging-predictive-factors-and-unmet-needs
#17
REVIEW
Stefano Cavalieri, Licia Rivoltini, Cristiana Bergamini, Laura D Locati, Lisa Licitra, Paolo Bossi
According to the new determinants of cancer immunity, head and neck squamous cell cancer (HNSCC) has to be considered as an immunogenic tumor for the relatively high number of somatic mutations giving rise to neoantigens recognized by T cell. HNSCC develop at a significant rate despite the antitumoral immune response indicating the existence of effective escape mechanisms. The lack of antigen presentation or co-stimulatory molecules required and immunosuppressive phenomena established by the tumor or the host microenvironment impair immune-mediated recognition and cancer control...
March 20, 2018: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29572791/expression-and-targeting-of-tumor-markers-in-gelfoam-%C3%A2-histoculture-potential-individualized-assays-for-immuno-oncology
#18
Robert M Hoffman, Fiorella Guadagni
Tumor-specific antigens are important in the study of tumor biology, tumor diagnosis, and prognosis and as targets for tumor therapy. This chapter reviews patient colon, breast, and ovarian tumors in 3-dimensional Gelfoam® histoculture maintaining in vivo-like expression of the important tumor antigens, for example TAG-72 and CEA. We have also reviewed that fluorescent antibodies can target tumors in Gelfoam® histoculture, thereby providing an assay for individual patients for sensitivity to therapeutic antibodies which have become so important in immuno-oncology and other cancer therapies...
2018: Methods in Molecular Biology
https://www.readbyqxmd.com/read/29563820/modeling-the-economic-outcomes-of-immuno-oncology-drugs-alternative-model-frameworks-to-capture-clinical-outcomes
#19
E J Gibson, N Begum, I Koblbauer, G Dranitsaris, D Liew, P McEwan, A A Tahami Monfared, Y Yuan, A Juarez-Garcia, D Tyas, M Lees
Background: Economic models in oncology are commonly based on the three-state partitioned survival model (PSM) distinguishing between progression-free and progressive states. However, the heterogeneity of responses observed in immuno-oncology (I-O) suggests that new approaches may be appropriate to reflect disease dynamics meaningfully. Materials and methods: This study explored the impact of incorporating immune-specific health states into economic models of I-O therapy...
2018: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/29563205/multicenter-validation-of-commercial-antigenuria-reagents-to-diagnose-progressive-disseminated-histoplasmosis-in-people-living-with-hiv-aids-in-two-latin-american-countries
#20
Diego H Cáceres, Blanca E Samayoa, Narda G Medina, Angela M Tobón, Brenda J Guzmán, Danicela Mercado, Angela Restrepo, Tom Chiller, Eduardo E Arathoon, Beatriz L Gómez
Histoplasmosis is an important cause of mortality in patients with AIDS, especially in countries with limited access to antiretroviral therapies and diagnostic tests. However, many disseminated infections in Latin America go undiagnosed. A simple, rapid method to detect Histoplasma capsulatum infection in endemic regions would dramatically decrease time to diagnosis and treatment, reducing morbidity and mortality. The aim of this study was to validate a commercial monoclonal Histoplasma galactomannan (HGM) ELISA (Immuno-Mycologics [IMMY], Norman, Oklahoma, USA) in two cohorts of people living with HIV/AIDS (PLHIV)...
March 21, 2018: Journal of Clinical Microbiology
keyword
keyword
50563
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"